Physician profile
James D Bailey
NPI 1912933995
$4,934.27
in general payments reported to CMS, 2019-2025
26 companies · $660 in 2025
The $660 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $452 · 2020: $334 · 2021: $512 · 2022: $1,088 · 2023: $1,042 · 2024: $847 · 2025: $660.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,549.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,548.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,102.99 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Astrazeneca Pharmaceuticals LP | $947.65 | 2019-2024 | Airsupra, Farxiga, Brilinta |
| Novo Nordisk INC | $777.68 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $424.55 | 2020-2025 | |
| Amgen INC. | $316.13 | 2021-2025 | Repatha, Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $183.91 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $170.14 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $139.15 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $119.61 | 2023-2025 | Xifaxan |
| Janssen Pharmaceuticals, INC | $114.44 | 2019-2021 | |
| Lilly USA, LLC | $106.50 | 2019-2023 | Mounjaro |
| Exact Sciences Corporation | $94.35 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbott Laboratories | $74.55 | 2023 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $61.48 | 2019-2024 | Shingrix, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.82 | 2020-2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $42.26 | 2021 | |
| Shield Therapeutics INC | $40.37 | 2024 | |
| Dexcom, INC. | $39.90 | 2023-2024 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $31.60 | 2023 | Nuedexta |
| Phathom Pharmaceuticals, INC. | $19.63 | 2024 | Voquezna |
| Allergan, INC. | $17.74 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $14.47 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $13.18 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.06 | 2022 | |
| Amarin Pharma, INC. | $12.55 | 2019 | |
| Dynavax Technologies Corporation | $10.56 | 2023 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.